Metrovacesa Past Earnings Performance
Past criteria checks 4/6
Metrovacesa has been growing earnings at an average annual rate of 54.1%, while the Real Estate industry saw earnings growing at 17.5% annually. Revenues have been growing at an average rate of 16.4% per year. Metrovacesa's return on equity is 4%, and it has net margins of 8%.
Key information
54.14%
Earnings growth rate
61.06%
EPS growth rate
| Real Estate Industry Growth | 17.43% |
| Revenue growth rate | 16.39% |
| Return on equity | 4.02% |
| Net Margin | 8.03% |
| Next Earnings Update | 22 Jul 2026 |
Recent past performance updates
Analysis Article • Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...Analysis Article • Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...Recent updates
Narrative Update • May 28
MVC: Slightly Lower Required Return And Rich P/E Will Shape Future Upside
Analysts have nudged their fair value estimate for Metrovacesa to €11.17 from €10.81, citing updated assumptions around the discount rate and future P/E, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: €11.17, up slightly from €10.81.Narrative Update • May 02
MVC: Slightly Higher Required Return And Rich P/E Will Constrain Future Upside
Analysts have kept their average price target for Metrovacesa broadly steady around €10.81, citing only slight shifts in discount rate, profit margin assumptions and future P/E expectations rather than any major change in the investment case. Valuation Changes Fair Value: The €10.81 fair value estimate is unchanged, indicating a stable central valuation point in the model.Narrative Update • Apr 17
MVC: Higher Required Return And Rich P/E Will Pressure Future Returns
Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.Narrative Update • Apr 03
MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns
Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.Narrative Update • Mar 20
MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance
Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.
Narrative Update • Mar 06
MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View
Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.Narrative Update • Feb 20
MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance
Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.Narrative Update • Feb 06
MVC: Lower Discount Rate And High P/E Will Sustain Bearish View
Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.Narrative Update • Jan 23
MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook
Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).
Narrative Update • Jan 08
MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis
Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.Narrative Update • Dec 24
MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook
Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.Analysis Article • Dec 20
Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate
Key Insights Metrovacesa's estimated fair value is €11.52 based on 2 Stage Free Cash Flow to Equity Current share price...Narrative Update • Dec 10
MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects
Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.Analysis Article • Oct 02
Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?
Metrovacesa S.A. ( BME:MVC ), is not the largest company out there, but it had a relatively subdued couple of weeks in...Analysis Article • Jul 25
Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €12.58 Metrovacesa's €10.15...Analysis Article • May 04
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Apr 12
Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?
Key Insights The projected fair value for Metrovacesa is €16.96 based on 2 Stage Free Cash Flow to Equity Metrovacesa...Analysis Article • Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
Even though Metrovacesa S.A.'s ( BME:MVC ) recent earnings release was robust, the market didn't seem to notice. We...
New Narrative • Feb 19
Will Leverage Undersupplied Spanish Housing Market For Future Opportunities
High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.Analysis Article • Feb 07
Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it maintained its current share price...Analysis Article • Dec 13
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued
Key Insights Metrovacesa's estimated fair value is €16.39 based on 2 Stage Free Cash Flow to Equity Metrovacesa's €9.13...Analysis Article • Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.93 based on 2 Stage Free Cash Flow to Equity Metrovacesa's...Analysis Article • Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve
The subdued stock price reaction suggests that Metrovacesa S.A.'s ( BME:MVC ) strong earnings didn't offer any...Analysis Article • Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it saw significant share price...Analysis Article • May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €9.31 Current share price...Analysis Article • May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not have the largest market cap around , it received a lot of attention from a...Analysis Article • Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
Key Insights The projected fair value for Metrovacesa is €9.08 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it saw significant share...Analysis Article • Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Metrovacesa fair value estimate is €7.36 Current share price...Analysis Article • Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?
While Metrovacesa S.A. ( BME:MVC ) might not be the most widely known stock at the moment, it received a lot of...Analysis Article • May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)
Does the May share price for Metrovacesa S.A. ( BME:MVC ) reflect what it's really worth? Today, we will estimate the...Analysis Article • Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality
Metrovacesa S.A. ( BME:MVC ) just reported healthy earnings but the stock price didn't move much. We think that...Analysis Article • Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?
Today we will run through one way of estimating the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by projecting its...Analysis Article • May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?
Is Metrovacesa S.A. ( BME:MVC ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...Analysis Article • Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 12% in the last month. But that...Analysis Article • Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven
We feel now is a pretty good time to analyse Metrovacesa S.A.'s ( BME:MVC ) business as it appears the company may be...Analysis Article • Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?
Metrovacesa S.A. ( BME:MVC ), might not be a large cap stock, but it led the BME gainers with a relatively large price...Analysis Article • Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)
In this article we are going to estimate the intrinsic value of Metrovacesa S.A. ( BME:MVC ) by taking the expected...Analysis Article • Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%
Metrovacesa S.A. ( BME:MVC ) shareholders should be happy to see the share price up 11% in the last month. But that...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Metrovacesa makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 708 | 57 | 51 | 0 |
| 30 Sep 25 | 632 | 27 | 51 | 0 |
| 30 Jun 25 | 555 | -3 | 51 | 0 |
| 31 Mar 25 | 604 | 6 | 52 | 0 |
| 31 Dec 24 | 653 | 16 | 54 | 0 |
| 30 Sep 24 | 651 | 17 | 53 | 0 |
| 30 Jun 24 | 649 | 18 | 53 | 0 |
| 31 Mar 24 | 616 | -15 | 53 | 0 |
| 31 Dec 23 | 581 | -21 | 52 | 0 |
| 30 Sep 23 | 535 | -68 | 51 | 0 |
| 30 Jun 23 | 430 | -71 | 52 | 0 |
| 31 Mar 23 | 454 | -38 | 51 | 0 |
| 31 Dec 22 | 516 | -23 | 51 | 0 |
| 30 Sep 22 | 529 | 25 | 57 | 0 |
| 30 Jun 22 | 572 | 33 | 56 | 0 |
| 31 Mar 22 | 575 | 31 | 55 | 0 |
| 31 Dec 21 | 512 | 18 | 53 | 0 |
| 30 Sep 21 | 413 | -71 | 47 | 0 |
| 30 Jun 21 | 231 | -90 | 40 | 0 |
| 31 Mar 21 | 138 | -160 | 34 | 0 |
| 31 Dec 20 | 140 | -164 | 34 | 0 |
| 30 Sep 20 | 164 | -87 | 34 | 0 |
| 30 Jun 20 | 180 | -87 | 34 | 0 |
| 31 Mar 20 | 214 | -6 | 35 | 0 |
| 31 Dec 19 | 161 | -4 | 34 | 0 |
| 30 Sep 19 | 206 | 0 | 33 | 0 |
| 30 Jun 19 | 220 | 5 | 31 | 0 |
| 31 Mar 19 | 211 | -11 | 28 | 0 |
| 31 Dec 18 | 190 | -9 | 29 | 0 |
| 30 Sep 18 | 103 | -14 | 23 | 0 |
| 30 Jun 18 | 70 | -31 | 26 | 0 |
| 31 Mar 18 | 34 | -34 | 18 | 0 |
| 31 Dec 17 | 28 | -39 | 15 | 0 |
| 30 Sep 17 | 29 | -55 | 11 | 0 |
| 31 Dec 16 | 21 | -21 | 7 | 0 |
| 31 Dec 15 | 36 | 64 | 8 | 0 |
Quality Earnings: MVC has a large one-off loss of €36.9M impacting its last 12 months of financial results to 31st December, 2025.
Growing Profit Margin: MVC's current net profit margins (8%) are higher than last year (2.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MVC has become profitable over the past 5 years, growing earnings by 54.1% per year.
Accelerating Growth: MVC's earnings growth over the past year (257.9%) exceeds its 5-year average (54.1% per year).
Earnings vs Industry: MVC earnings growth over the past year (257.9%) exceeded the Real Estate industry 73.5%.
Return on Equity
High ROE: MVC's Return on Equity (4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 06:03 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metrovacesa S.A. is covered by 22 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ignacio Romero | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Mariano Miguel Hidalgo | Banco Santander |